Kyverna Therapeutics: $145 Million Raised To Engineer New Class Of Therapies For Autoimmune Diseases
By Amit Chowdhry ● Aug 25, 2023
Kyverna Therapeutics - a clinical-stage cell therapy company with the mission of engineering a new class of therapies for autoimmune diseases - recently announced the closing of an oversubscribed $60 million Series B financing round extension, bringing the total Series B financing round to $145 million. New investors Bain Capital Life Sciences and GordonMD Global Investments LP join existing investors Gilead Sciences, Westlake Village BioPartners, Vida Ventures, Northpond Ventures, RTW Investments, Insight Partners, CAM Capital, LYFE Capital, jVen Capital, and others.